How one startup foretold the neuroscience renaissance after '50 years of shitshow'
In the past couple of years, something curious has happened: Pharma and VC dollars started gushing into neuroscience research.
Biogen’s controversial new Alzheimer’s drug Aduhelm …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
